Genomic Valley Biotech Ltd Financials
Company Logo

Genomic Valley Biotech Ltd Financial Statement

Genomic Valley Biotech Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue0.21
Operating Expense0.06
Net Profit0.15
Net Profit Margin71.43
Earning Per Share0.48
EBIDTA0.15
Effective Tax RateTBA

Genomic Valley Biotech Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
Total Revenue Annual2.72
Operating Expenses Annual1.84
Operating Profit Annual0.66
Interest AnnualTBA
Depreciation0.01
Net Profit Annual0.65
Tax Annual0.00

Genomic Valley Biotech Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
Cash Flow at the BeginningTBA
Cash Flow from Operations-0.78
Cash Flow from Investing1.52
Cash Flow from Financing-0.70
Cash Flow at the End0.04

Genomic Valley Biotech Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
PBDIT Margin (%)33.82
PBIT Margin (%)33.46
PBT Margin (%)33.46
Net PROFIT Margin (%)23.90
Return On Networth / Equity (%)28.48
Return On Networth /Employed (%)25.67
Return On Assets (%)18.40
Total Debt / Equity (X)TBA
Asset Turnover Ratio (%)0.77

Genomic Valley Biotech Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
Fixed Assets Annual0.00
Total Current Assets Annual2.58
Non Current Assets Annual1.84
Total Shareholders Funds Annual3.53
Total Assets Annual4.42

Genomic Valley Biotech Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Nov 5, 2024, Genomic Valley Biotech Ltd has a market capitalization of 10.60 Cr. Value Research classifies it as a Micro-Cap company.
Yes, Genomic Valley Biotech Ltd is debt-free with a debt-to-equity ratio of 0.00.
In FY 2023 , Genomic Valley Biotech Ltd recorded a total revenue of approximately 0.17 Cr marking a significant milestone in the company's financial performance.
Genomic Valley Biotech Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately Infinity% and 0.4% annually, respectively..
Genomic Valley Biotech Ltd's current PE ratio is 530.00.
Genomic Valley Biotech Ltd's ROCE averaged 5.3% from the FY ending March 2022 to 2024, with a median of 0.4%. It peaked at 25.9% in March 2023, reflecting strong capital efficiency over the period..
Genomic Valley Biotech Ltd's latest EBIT is Rs. 0.02 Cr, surpassing the average EBIT of Rs. 0.24 Cr over the 5 years..